Work

Uncovering cantharidin’s mechanism for cholangiocarcinoma treatment using patient-derived tumor organoids

Year: 2025

Type: article

Abstract: and in patient-derived organoids-based xenografts. These effects were reversible upon treatment with a p-ERK agonist, confirming pathway specificity. The study highlights cantharidin's potential as a targeted therapeutic agent in CCA and underscores the utility of PDOs in personalized drug screening and mechanistic investigation.

Source: iScience

DOI: 10.1016/j.isci.2025.114136

Authors: Pinsheng Han, Libo Wang, Liuyang Zhu, Wen Tong, Sen Liu, Tianze Wang, Tianrun Yang, ZhenZhen Li, Xiaolei Zhou, Tianyu Zhao, Tao Cui, Long Yang, Ze Wang, Yamin Zhang

Institutions: Nankai University, Tianjin Institute of Pharmaceutical Research (China), Tianjin First Center Hospital, Tianjin Medical University, Shenyang Pharmaceutical University

Language: English

Topic: Beetle Biology and Toxicology Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,240

Funders: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Tianjin Science and Technology Program

Awards: G3000305732, G3721496556, G4326503854, G5996512682, G6994778641, G7524421476, G923383612

OpenAlex ID: W4416426299

FWCI:

Cites: 48

Cited by:

Related to: